Healthcare
IDEAYA Biosciences, Inc.(IDYA)
Live Price
Offline$34.23
+9.61% today
1Y Change
+64.83%
Window
Jun 25, 2025 โ Jun 24, 2026
- Market Cap
- $2.56B
- Revenue Growth
- +3024.4%
- EPS Growth
- +61.9%
- Dividend Yield
- 0.0%
Coverage: 250 bars ยท Jun 25, 2025 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
IDEAYA Biosciences, Inc. (IDYA) is a Healthcare stock with a market cap of $2.56B and listed on NASDAQ. The stock last traded around $34.23 and up 64.8% across the available one-year price window (Jun 25, 2025 โ Jun 24, 2026). Baseline metrics include revenue growth of +3024.4%, EPS growth of +61.9%, a dividend yield of 0.0%. What stands out right now is revenue +3024.4%, EPS +61.9%, free cash flow +70.8% with operating margin -72.8% and ROIC -15.2%. Valuation already assumes a fairly strong business story at price/sales 11.7. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines IDYA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+3024.4% vs +7.6% peer median
Operating Margin
Below sector median
-72.8% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 5, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +3024.4% and EPS at +61.9%, with operating margin around -72.8%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +2.3% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 5, 2026 | โ | -0.2% | -2.4% | -1.4% |
2026 Feb 17, 2026 | +1.2% | +0.5% | +4.3% | +11.4% |
2025 Nov 4, 2025 | +240.6% | -2.7% | +5.0% | +12.7% |
Benchmark Edge
IDYA vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
IDYA
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
IDYA Max Drawdown
-27.10%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for IDYA and SPY.
Company Overview
IDEAYA Biosciences, Inc.
NASDAQ Global Select
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
- Leadership
- Yujiro S. Hata
- IPO Date
- May 23, 2019
- Employees
- 131
- Street Address
- 7000 Shoreline Court
- Mailing
- South San Francisco, CA, 94080
- Region
- South San Francisco, CA, US
- Reporting Currency
- USD
- Investor Line
- 650 443 6209
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 11.7
- Price/Book
- 2.5
Growth
- Revenue
- +3024.4%
- EPS
- +61.9%
- Free Cash Flow
- +70.8%
Profitability
- Gross Margin
- 97.9%
- Operating Margin
- -72.8%
- Net Margin
- -52.0%
- ROE
- -11.1%
- ROIC
- -15.2%
Balance Sheet
- Debt/Equity
- 0.05
- Current Ratio
- 11.34
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.